A Portacath or PICC Line Attracts Young Alpha-1 Patients
I knew some alpha-1 antitrypsin deficiency (AATD) patients have Portacaths and now I understand why.
Pulmonologists
FSH Levels Predict Severity and Survival in Men With Idiopathic PAH
A Chinese research team has determined that levels of follicle-stimulating hormone (FSH) are higher in men with idiopathic pulmonary arterial hypertension (IPAH) and these levels strongly predict survival and disease severity. The study, published in the American Journal of Men’s Health, retrospectively reviewed the records of 116 men with IPAH who were hospitalized between 2016…
SIRT3 Enzyme Could Help Develop New PAH Therapies
The sirtuin 3 (SIRT3) enzyme may prevent the development of cardiovascular diseases such as pulmonary arterial hypertension (PAH) by protecting the mitochondria, according to a new review published in Free Radical Biology and Medicine. Therefore, sirtuin 3 agonists may serve as potential treatments for cardiovascular diseases, the authors said. SIRT3 is a deacetylase that regulates…
Breathing Reserve at Peak Exercise May Not Provide IPAH Prognostic Value
Researchers discovered that patients’ breathing reserve at peak exercise was not associated with disease outcomes in idiopathic pulmonary arterial hypertension (IPAH), as published in the International Journal of Cardiology Congenital Heart Disease. In contrast, they found an association between breathing reserve >30% at peak exercise and improved survival rates in patients with Eisenmenger syndrome (EIS).…
How Telomere Dysfunction Drives Pathogenesis in IPF
We explore how telomere dysfunction potentially drives the pathogenesis of idiopathic pulmonary fibrosis, and what that could mean for future research.
Coadministration of Cudetaxestat Shows Success in IPF Phase 1 Trial
Blade Therapeutics successfully completed phase 1 studies evaluating the coadministration of cudetaxestat with existing approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF), according to a news release. Cudetaxestat is an investigative, noncompetitive autotaxin inhibitor that was developed by Blade Therapeutics for the treatment of IPF and other fibrotic illnesses. The phase 1 study…
Untreated IPF Associated With 50% All-Cause Mortality, Study Finds
Idiopathic pulmonary fibrosis (IPF) is associated with a 50% all-cause mortality at 3 years if not treated with antifibrotics, according to the results of an observational study published in Frontiers in Medicine. “These figures can serve as a historical control of the natural course of the disease,” Vincent Cottin, MD, PhD, and the coauthors of…
New Imaging Tracking System Could Clarify Stem Cell Role in IPF Therapy
Researchers developed a new imaging tracking system for the treatment of idiopathic pulmonary fibrosis (IPF) that is a noninvasive and real-time tracking method of transplanted human mesenchymal stem cells under nintedanib. This new system offers new insight into the role of stem cells in combination with small drugs in the treatment of IPF and advanced…
New Assay Can Measure Lower Active AAT Levels in AATD
A new method of measuring the levels of alpha-1 antitrypsin (AAT) activity in a sensitive and specific manner was discovered, as published in the Journal of Pharmaceutical and Biomedical Analysis. “The data obtained demonstrated the ECFISA [elastase complex formation immunosorbent assay] as an accurate, precise, selective, and very sensitive method for AAT activity measurement at…
Exploring the Cause and Effect of Endothelial Dysfunction in PAH
Endothelial dysfunction is a prominent feature of pulmonary arterial hypertension. We explore the cause and effects of it.
- Loading...
Loading...
Next post in PAH Insights
Loading... 
Loading...